KR102255499B1 - Novel antioxidant peptides and pharmaceutical composition for preventing or treating cardiovascular disease - Google Patents

Abstract

In the present invention, the peptide isolated and purified from the alkylase hydrolyzate of the antler enzyme hydrolyzate has excellent antioxidant efficacy and has angiotensin converting enzyme inhibitory activity, thus exhibiting an effective blood pressure control effect and antihypertension effect in the body. , Peptides isolated and purified from the alkylase hydrolyzate of the antler enzymatic hydrolyzate can be usefully used as an active ingredient in a pharmaceutical composition for improving blood pressure or preventing cardiovascular disease and a health functional food for improving cardiovascular disease.

Description

Novel antioxidant peptides and pharmaceutical composition for preventing or treating cardiovascular disease containing the same

The present invention confirms the angiotensin converting enzyme (ACE) inhibitory ability of a peptide with excellent antioxidant activity isolated and purified from Alcalase hydrolyzate among Velvet Antler enzyme hydrolysates, and , It relates to a pharmaceutical composition for preventing or treating cardiovascular diseases using the peptide as an active ingredient.

Antler (Velvet Antler, Latin name: cervi parvum cornu) refers to the young horns of the stag belonging to the deer family (cervidae) with soft, evenly covered hairs. In autumn, the soft and fluffy horns become hard and keratinized, and this is for the fight to take over females in the heat of estrus, and these keratinized horns are called nokgak. . Oriental medicine has long been regarded as the best blood tonic, and as reported in the literature such as Donguibogam, deer antlers are known to have various effects such as analgesic, hematopoietic, initial growth and development, heart failure treatment, and renal function. Recently, several studies have reported that antler has pharmaceutical effects such as anticancer, anti-inflammatory, antioxidant, antibacterial, and antiviral, and it has been reported to regulate immune and vascular system and glucose and bone metabolism. In addition, proteins rich in superoxide dismutase, sterols, glycolipids, and vitamins, and polypeptides isolated from antlers are used in epidermal cells and BRL stem cells. , Buffalo rat liver cells), various modern medical studies on antlers such as the effect on proliferation have been conducted.

However, since most of the conventional extracts have unpleasant odors and colors, it is difficult to apply them as foods and medicines, and diversify the extraction methods to increase the utility value of antlers as a variety of materials, and how to easily consume them. There is a need for improvement and research.

Cardiovascular disease is an abnormality in the heart and vascular system, and includes heart disease, central blood vessels such as the aorta, and peripheral blood vessels in lower organs and tissues. According to the statistics of the World Health Organization (WHO), the number of deaths due to cardiovascular disease is on a sharp increase every year worldwide, and it is reported that the rate of increase is high, especially in Asia such as Japan and Korea. This is presumed to be due to an increase in risk factors for coronary artery disease due to changes in access to an aging society and eating habits.

The major factors in the expression of cardiovascular disease are genetic factors, lifestyle habits, diabetes, etc., are widely known, but from the viewpoint of modern medicine, reactive oxygen species (ROS) and blood vessels are associated with increased activity of NADPH oxidase. It is known to be due to a decrease in nitric oxide due to an increase in internal oxidative stress and a decrease in the activity of endothelial type nitric oxide synthase (eNOS).

Cardiovascular diseases include hypertension, arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications of acute transangioplasty, cerebral infarction, cerebral hemorrhage, and stroke. It is not limited thereto.

Hypertension, a representative cardiovascular disease, is emerging as a globally untapped disease that accounts for 15 to 20% of the adult disease rate, and although relatively symptom-free, hypertension suffers from other cardiovascular diseases such as arteriosclerosis, stroke, myocardial infarction and end-stage kidney disease. It is known that the risk of complications increases, so more active management and treatment are required.

Most of the causes of hypertension have not been identified, but it is known to occur as a complex product of genetic factors such as family history, ethnic salt intake, insulin resistance and obesity, or environmental factors such as excessive drinking and aging. Among the misconceptions, the renin-angiotensin-aldosterone ring is known to play an important role in regulating blood pressure and fluid volume in vivo. (Weiss, D et al, 2001, Circulation 103:448-454)

Essential hypertension accounts for about 90% of the total hypertension, and angiotensin Ⅰ in the blood is converted to angiotensin Ⅱ by angiotensin converting enzyme (ACE), constricting blood vessels, and aldosterone in the kidney. It is known that by increasing the secretion and increasing the amount of fluid, it causes an increase in blood pressure, resulting in hypertension, which lowers the essential blood pressure. Therefore, by inhibiting ACE activity, inhibiting angiotensin I converting enzyme (ACE), which causes blood pressure to rise, is an important therapeutic approach to control hypertension, and substances that inhibit ACE or angiotensin converting enzyme inhibitors (ACE inhibitors) are high blood pressure. Is expected to treat and prevent, and many studies are being conducted on this, and chemically synthesized angiotensin converting enzyme inhibitors such as ramipril, captopril, and enarapril are commercial hypertension treatments. Although used, it is reported to have side effects such as vomiting, cough, loss of appetite, and headache, and development of safe ACE inhibitors that do not show side effects to the human body is required.

Until now, Korean Patent Application Publication Nos. 10-2012-0092735, 10-2014-0049628, etc. disclose peptides that exhibit ACE inhibitory activity from natural substance-derived ACE inhibitors and from natural substance enzyme hydrolysates, but are still functionally derived from natural substances. There is an increasing demand for peptide development.

Therefore, the inventors of the present invention confirmed that the Alcalase hydrolyzate of the deer antler enzyme hydrolyzate has antioxidant activity, and a novel peptide characterized by the antioxidant activity from the Alcalase hydrolyzate. Was isolated and purified, and the peptide exhibits ACE activity inhibitory activity and blood pressure lowering effect, so the peptide having antioxidant activity isolated from the Alcalase hydrolyzate of the deer antler enzyme hydrolyzate of the present invention prevents cardiovascular disease. And by confirming that it can be usefully used as an active ingredient of a therapeutic pharmaceutical composition, the present invention was completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating cardiovascular diseases, comprising as an active ingredient a peptide having antioxidant activity consisting of an amino acid sequence represented by SEQ ID NO: 1 or 2.

Another object of the present invention is to provide a food for preventing or improving cardiovascular diseases, comprising as an active ingredient a peptide having antioxidant activity consisting of an amino acid sequence represented by SEQ ID NO: 1 or 2.

In order to achieve the above object, the present invention provides a peptide consisting of the amino acid sequence described in SEQ ID NO: 1 or 2.

The peptide is characterized by having antioxidant activity.

The peptide is a peptide characterized in that it is isolated from an antler enzyme hydrolyzate, and it is characterized in that it is isolated from a fraction of less than 5 kDa in the alcalase hydrolyzate of the hydrolyzate.

The peptide is characterized by having an angiotensin converting enzyme inhibitory activity.

The peptide has a blood pressure lowering effect.

In addition, the present invention provides a pharmaceutical composition for preventing or treating cardiovascular diseases using the peptide as an active ingredient.

In addition, the present invention provides a health functional food composition for improving cardiovascular diseases using the peptide as an active ingredient.

The peptide isolated from the fraction of the alkylase hydrolyzate of the deer antler enzyme hydrolyzate of the present invention exhibits angiotensin converting enzyme inhibitory activity and blood pressure lowering effect. ) The peptide isolated from the fraction of hydrolyzate can be usefully used as an active ingredient in a pharmaceutical composition for preventing or treating cardiovascular diseases.

1 is a result showing the radical (peroxyl radical) scavenging activity of a fraction separated through gel filtration chromatography of a fraction of 5 kDa or less.
Figure 2 is a result showing the radical (peroxyl radical) scavenging activity of the fraction separated by reverse phase-high performance liquid chromatography of the F3 fraction.
3 is a result showing the amino acid structure and molecular weight of the peptide obtained through separation and purification.
4 is a result showing the ROS scavenging activity of peptides 1 and 2 in the zebrafish model.
Figure 5 is a result showing the inhibitory effect of the angiotensin I-converting enzyme (ACE) of peptides 1 and 2.
6 is a result showing the blood pressure lowering effect of peptides 1 and 2 through congenital hypertensive mice (SHR).

Hereinafter, the present invention will be described in detail. Embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those of ordinary skill in the art can easily implement the present invention. However, the present invention may be implemented in various different forms, and is not limited to the embodiments described herein.

The present invention provides a peptide characterized by having an antioxidant activity consisting of a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 (peptide 1) or 2 (peptide 2).

The peptide is preferably isolated from an Alcalase hydrolyzate among the deer antler enzyme hydrolyzate, but is not limited thereto, and any one derived from another material or synthesized may be used.

As a method for the separation, it is preferable to use a conventional separation method in the art such as ultrafiltration and chromatography. Specifically, it is preferable to use a chromatography method, and anion exchange chromatography It is most preferable to use anion exchange chromatography, size exclusion chromatography, reverse-phase chromatography, or high performance liquid chromatography (HPLC). Not limited.

The peptide is characterized by having antioxidant activity, and “antioxidation” refers to an action of inhibiting oxidation, and in the human body, an oxidation promoting substance (pro-oxidant) and an antioxidant substance (antioxidant) are in balance, but various Due to various factors, this balance is unbalanced, and when it is tilted toward the promotion of oxidation, oxidative stress is induced, leading to potential cell damage and pathological disease. Reactive Oxygen (ROS), which is a direct cause of oxidative stress, is unstable and highly reactive, reacts easily with various biological substances, and attacks macromolecules in the body, causing irreversible damage to cells and tissues. Or cause mutations, cytotoxicity and carcinogenesis. Reactive nitrogen species (RNS) such as NO, HNO ₂ , and ONOO-, and reactive oxygen species such as ROS oxidize and destroy cells in the body, thereby being exposed to various diseases. In addition, the antioxidant refers to a function of inhibiting the oxidation of cells by free radicals or reactive oxygen species (ROS) that are highly reactive according to phosphoric acid oxidative stress under the influence of intracellular metabolism or ultraviolet rays, and free radicals or It includes removing reactive oxygen species, thereby reducing damage to cells.

In addition, the peptide consisting of the amino acid sequence described in SEQ ID NO: 1 or 2 of the present invention is a peptide containing a fraction of less than 5kDa among the hydrolyzates of antler alkylase (Alcalase) as an active ingredient, and the fraction is preferably 5KD or less. , Is not limited thereto.

In addition, the present invention is a peptide isolated and purified from an alkylase hydrolyzate of antler enzyme hydrolyzate, and exhibits angiotensin converting enzyme inhibitory activity and blood pressure control effect. ) Peptides isolated and purified from hydrolysates can be usefully used as a pharmaceutical composition for preventing or treating cardiovascular diseases.

The cardiovascular disease includes hypertension, arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications resulting from transvascular angioplasty, cerebral infarction, cerebral hemorrhage, and stroke. , But is not limited thereto.

The pharmaceutical composition of the present invention can be preferably formulated using a suitable method known in the art.

The composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, drug activity, drug Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. In consideration of all the above factors, it is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects, which can be easily determined by a person skilled in the art. The dosage of the composition of the present invention varies according to the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease. However, since it may increase or decrease depending on the route of administration, the severity of obesity, sex, weight, age, etc., the dosage amount does not limit the scope of the present invention in any way.

The composition of the present invention may be used alone or in combination with methods using biological response modifiers such as surgery, radiation therapy, hormone therapy, and chemotherapy.

In addition, the present invention is a peptide isolated and purified from an alkylase hydrolyzate of antler enzyme hydrolyzate, and exhibits an angiotensin converting enzyme inhibitory activity and blood pressure control effect in the body. It can be usefully used as an active ingredient in health food for improvement.

There is no particular limitation on the type of the food. Examples of foods to which the above substances can be added include drinks, meats, sausages, bread, biscuits, rice cakes, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, milk products, or Special nutrient foods such as infant and toddler meals, processed food products, fish meat products, tofu, jelly, health supplements, seasoning foods such as soy sauce, soybean paste, red pepper paste or mixed sauce, sauces, other processed foods, pickled foods such as kimchi or pickles, various soups , Beverages, alcoholic beverages and vitamin complexes, dairy and dairy products, etc., and all health functional foods in the usual sense are included. The food, beverage or food additive may be prepared by a conventional manufacturing method.

In the invention of the ball, “health food” refers to a food group or food composition that has added value to act and express the function of the food for a specific purpose by using physical, biochemical, or biotechnological methods of the food. And it means a food that is designed and processed to sufficiently express the gymnastic function related to recovery, etc. to a living body, and preferably, the health food of the present invention sufficiently expresses the gymnastic function related to the prevention or improvement of hypertension in the living body. It means food that can be done. The health food may contain food additives acceptable food additives, and may further include suitable carriers, excipients, and diluents commonly used in the manufacture of health foods.

Among the antler enzyme hydrolysates of the present invention, the peptide isolated from the alkylase hydrolyzate may be added to food as it is or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement).

In addition to the above, the peptides isolated from the alkylase hydrolyzate of the antler enzyme hydrolyzate of the present invention are various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and natural flavoring agents, etc., colorants and enhancers ( Cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal focus agents, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, etc. . In addition, the peptide isolated from the Alcalase hydrolyzate of the antler enzyme hydrolyzate of the present invention may contain flesh for the manufacture of natural fruit juice and fruit juice and fruit juice beverage and vegetable beverage. These components may be used independently or in combination.

Hereinafter, the present invention will be described in detail by examples.

Experimental material

Antlers were supplied from Daeseongsan Deer Farm (Korea). Fresh antlers from deer farmed for 75 days obtained from deer were frozen at -20°C using a bone slicer. Then, the frozen pieces are dried with a Freeze dryer (Ilshin Lab Co., Ltd, Gyeonggi, Korea), and then pulverized using a grinder (HMF-3100S; Hanil Co., Gyeongbukgong, Korea). Was used.

Preparation of antler enzymatic hydrolyzate

Using the dried antler, for hot water treatment, 1g of antler powder is added to 100ml of purified water and cultured by shaking at 70°C for 24 hours. Then, it was centrifuged at 3000 rpm for 20 minutes at 4° C. and filtered. 1 g of dried antler powder was added to 100 ml of purified water, and the optimum temperature of each enzyme (Trypsin, Neutrase, Pepsin, a-chymotrypsin, Alcalase) was adjusted under the pH and temperature conditions as shown in Table 1 below, and then each enzyme was It was put in 100:1 (weight ratio) and hydrolyzed. After the reaction was over, in order to inactivate the enzyme, it was boiled for 10 minutes at 100° C., and centrifuged at 3000 rpm for 20 minutes to remove the non-hydrolyzed residue, and then the pH was adjusted to 7.

Extraction yield and peroxyl radical scavenging activity of antler enzyme hydrolyzate Hydrolyzate Extraction yield (%) Peroxyl radical scavenging activity (%, 1mg/ml) Hot water extract 22.00 79.92±2.56 Trypsin 34.09 90.00±1.69 Neutrase 23.81 89.97±1.05 Pepsin 12.89 78.58±1.08 α-Chymotrypsin 38.96 89.54±0.42 Alcalase 29.75 93.78±0.45

Antioxidant Activity Measurement of Fractions by Molecular Weight of Alcalase Hydrolyzate from Antler Enzyme Hydrolyzate

As shown in Table 1 above, Alcalase hydrolyzate showing strong antioxidant activity was finally selected, and a fraction containing a peptide having strong antioxidant activity was separated using ultrafiltration, gel filtration, and HPLC method. Using ultrafiltration membranes (Millipore's Lab scale TFF system, Millipore Corporation, Bedford, Massachusetts, USA), the hydrolyzate was separated by >10kDa (10kDa), 5-10 kDa, <5kDa (less than 5kDa) molecular weight. .

In the present invention, the measurement of radical scavenging activity was measured using an electron spin resonance spectrometer (ESR, JEOL, Tokyo, Japan), and the result shows the concentration IC ₅₀ value (the inhibitory concentration of 50% scavenging activity).

The measurement of the radical scavenging activity (peroxyl radical scavenging activity) was measured by the Hiramoto (1993) method. Mix 20ul of 40 mM 2,2′-azobis (2-amidinopropane) dihydrochloride (AAPH) solution and 20ul of 40 mM 4-POBN with 20ul of phosphate buffered-saline (PBS) and 20ul for sample, and mix the mixed solution for 30 minutes. During the treatment in a constant temperature water bath at 37 ℃ and measured with an electronic spin resonance instrument (ESR).

Table 2 shows the results of measuring the antioxidant activity according to the molecular weight fraction (Fraction) of the Alcalase hydrolyzate of the antler enzyme hydrolyzate. As a result, it was confirmed that the antioxidant activity was excellent in the fraction (Fraction) of <5 kDa (less than 5 kDa).

Extraction Yield and Peroxyl Radical Scavenging Activity of Fractions by Molecular Weight of Alcalase Hydrolyzate from Antler Fraction Yield (%) Peroxyl radical scavenging activity IC ₅₀ value (mg/ml) Fractions of 10 kDa or more 24.49 0.30±0.01 5-10 kDa fraction 29.35 0.35±0.01 Fractions up to 5 kDa 40.52 0.26±0.02

Isolation and purification of peptides with antioxidant activity

In Example 3, in order to purify the peptide of <5 kDa (less than 5 kDa) of the fraction of the alkylase hydrolyzate having the best antioxidant activity, SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) Then, in order to separate the functional peptide having antioxidant activity with MW (Molecular weight) 1000-5000 Da (dalton), a size exclusion column containing Sephadex G-25 was used, Using size exclusion chromatography, four fractions F1, F2, F3, and F4 were obtained as shown in Fig. 1, and the alkyl radical scavenging activity in the experimental method of measuring the antioxidant activity of the four fractions. ) In the result from the measurement (IC50 value, F1: 1.25 mg/ml. F2: 0.28 mg/ml F3: 0.12 mg/ml, F4: 0.29 mg/ml). _{The F3 fraction, which has an IC 50} value of 0.12mg, which shows an antioxidant activity effect in, was fractionated by reverse-phase-high performance liquid chromatography (HPLC). The conditions of use were YMC-Pack ODS-A column column (5μm, 4.6×250mm, YMC Co., Kyoto, Japan), and 220nm while flowing acetonitrile (acetonitrile, 0-100%) at a rate of 1.0ml/min. The absorbance was measured at. As a result, as shown in Figure 2, F3-1, F3-2, F3-3, F3-4 F3-5 total 5 fractions were eluted, F3-2 excellent in antioxidant activity by measuring radical scavenging activity among the total 5 fractions. And F3-3, mass spectrometry (quantitative time of flight ESI mass spectroscopy: electrospray ionization, ESI method), ions can be separated according to the ratio of mass per charge, Cliotid analysis is possible) to confirm the amino acid sequence.

As a result, as shown in Fig. 3, two SEQ ID NO: 1 (Asp-Asn-Arg-Tyr-Tyr, DNRYY, 729.32 Da, F3-2, peptide 1) or 2 (Trp-Asp-Val-Lys, WDVK 547.29 Da, F3) A peptide consisting of the amino acid sequence described as -3, peptide2) was identified.

Cytotoxicity using Chang cells of isolated and purified peptides

Cytotoxicity to the peptides isolated and purified in Example 4 was confirmed, and after confirming the result that there was no cytotoxicity, the intracellular antioxidant effect was further confirmed.

To confirm the cytotoxicity of the peptide, heat-inactivated fetal bovine serum (FBS) and 1% (v/v) antibiotics (antibiotic.Culture) by heat-treating chang liver cells, one of the hepatocytes. ) Was inoculated into DMEM medium, and cultured in a cell incubator to maintain _{5% CO 2 at 37°C.} When the cells cover an 80% cell culture dish, they were washed twice with physiological saline, treated with Trypsin, and subcultured, and the cells were cultured at a ^{concentration of 1×10 5} cells/ml in a 96 well plate. The cells were prepared by aliquoting. Then, after 16 hours, the peptides isolated and purified in Example 4 were treated at 12.5, 25, 50, 100, 200, 400 μg/ml concentrations and incubated at 37° C. for 4 hours, and purple insoluble formazan (formazan crystal) with DMSO. ) Melted, and the absorbance was confirmed at 540nm. Cell viability (cell viability) of the peptide was 100% or more compared to the control group, and no cytotoxicity was observed.

Confirmation of antioxidant efficacy in zebrafish model of isolated and purified peptides

The zebrafish is a model that is in the spotlight as an experimental animal that can replace the mouse, which is an experimental animal model, has a fast life history, and has high genetic homology to humans, so it is a model that is widely used in human diseases and research. Zebrafish were purchased from Seoul aquarium (Seoul, Korea) and were maintained in a light/dark cycle of 14/10h per day in a 28.5±1℃, 3.5 L acrylic tank. Zebrafish were fed twice a day with Tetra GmgH D-4304 (Melle Made in Germangy). In zebrafish, AAPH was also used as a stimulator to induce oxidative stress. As a result of confirming the antioxidant efficacy in the zebrafish model of the peptides isolated and purified as follows, the production of reactive oxygen species (ROS) was significantly reduced, and the peptide was confirmed to have antioxidant activity.

Active oxygen (ROS) measurement in the zebrafish model

To measure active oxygen (ROS) in zebrafish, transfer the sample solution and the zebrafish treated with AAPH (irritant) from a 12 well plate to a 96 well plate and add DCFH-DA solution (20 ug/ml) to 1 The reaction was carried out in a dark room at 28.5±1° C. for a period of time, and the amount of ROS produced was measured. After the reaction was over, it was washed with new embryo media, anesthetized with 2-phenoxy ethanol (diluted to 1:500 weight, sigma), and observed using a fluorescence microscope, and quantified using the image J program. Figure 4)

Confirmation of the ability of isolated and purified peptides to inhibit the activity of angiotensin-converting enzyme (ACE)

To the peptide isolated from the Alcalase hydrolyzate of antler deer isolated and purified in Example 4 Angiotensin-converting enzyme (ACE) activity inhibition activity was confirmed using an ACE kit (WST® assay kit). The ACE kit assay is safe and highly sensitive. Mix the sample solution and deionized water (control), put it in a 96 well plate (well plate), put the substrate buffer and enzyme mixture in each well, and then at 37℃ After incubation at for 60 minutes, the reacted solution (working solution) was measured for absorbance at 450 nm. The IC ₅₀ value was defined as the peptide concentration (μg/ml) required to inhibit ACE activity by 50%. As shown in Figure 5, it was confirmed that the ACE activity inhibiting ability was shown.

Confirmation of the effect of isolated and purified peptides on regulating blood pressure in vivo

In order to confirm the blood pressure control effect of the peptide isolated from the deer antler alcalase hydrolyzate in vivo, the peptide was orally administered to hypertensive mice and the blood pressure control effect was confirmed.

Specifically, 10 weeks of age (Spontaneously hypertensive rats, SHR; SLC Inc. Shizuoka, Japan, systolic blood pressure, systolic blood pressure: 180mmHg) 250-300g body weight. In a breeding environment of ±1℃, humidity of 55±5%, and a light and dark cycle of 12 hours, feed and water were sufficiently supplied to allow free intake, and stabilized for 1 week.

The peptide prepared in Example 4 was put in physiological saline water and orally administered to a rat with essential hypertension at 50 mg/kg using a metal oral administration zone. The systolic blood pressure control group was orally administered in physiological saline at the same volume. After oral administration, preparations were made at 37° C. for 30 minutes, and then the systolic blood pressure of the tail cuff of the rat was measured using a CODATM blood pressure monitor (Kent Scientific Corp., Torrington, USA). As a result of measuring systolic blood pressure 0, 3, 6 and 9 hours after oral administration by the above method, it was confirmed that the systolic blood pressure decreased 6 hours after oral administration as shown in FIG. After 9 hours, it was confirmed that the systolic blood pressure did not increase in the peptide consisting of SEQ ID NO: 1 among the peptides isolated and purified in Example 4, compared with the control group. Therefore, it was confirmed that the peptide isolated and purified from the alkylase hydrolyzate of the antler enzyme hydrolyzate has good antihypertensive activity.

<110> SCH <120> Novel antioxidant peptides and pharmaceutical composition for preventing or treating cardiovascular disease <130> M19-999C <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> velvet antler <400> 1 Asp Asn Arg Tyr Tyr 1 5 <210> 2 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> velvet antler <400> 2 Trp Asp Val Lys One

Claims (11)

Peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 (Asp-Asn-Arg-Tyr-Tyr) or SEQ ID NO: 2 (Trp-Asp-Val-Lys)
The peptide according to claim 1, wherein the peptide has antioxidant activity.
The peptide according to claim 1, wherein the peptide is isolated from an antler enzyme hydrolyzate.
The peptide according to claim 3, wherein the hydrolyzate is isolated from an Alcalase hydrolyzate.
The peptide according to claim 4, wherein the alkylase (Alcalase) hydrolyzate is isolated from a fraction of less than 5 kDa.
The method of claim 1, wherein the peptide is a peptide having an angiotensin converting enzyme inhibitory activity.
The method of claim 6, wherein the peptide is a peptide having a blood pressure lowering effect.
Selected from the group consisting of hypertension, arteriosclerosis, heart disease, thrombosis, angina pectoris, heart failure, myocardial infarction, atherosclerosis and arteriosclerosis, cerebrovascular disease and stroke using the peptide according to any one of claims 1 to 7 as an active ingredient. Pharmaceutical composition for preventing or treating one or more cardiovascular diseases
Selected from the group consisting of hypertension, arteriosclerosis, heart disease, thrombosis, angina pectoris, heart failure, myocardial infarction, atherosclerosis and arteriosclerosis, cerebrovascular disease and stroke using the peptide according to any one of claims 1 to 7 as an active ingredient. One or more health food composition for improving cardiovascular disease
delete delete

Images